Press’d Kratom Tablets: What They Are and Where the Law Stands

Press’d, also written Press’d Botanicals and often searched as “pressd” or “pressed,” is one of a number of companies selling pressed kratom-alkaloid tablets. If you are researching the brand, the regulatory position matters as much as the product, so this page covers both.

Status check, September 2026. Mitragynine pseudoindoxyl, MGM-15 and MGM-16 became Schedule I controlled substances on 26 August 2026 under a DEA temporary scheduling order, with no quantity threshold and no retail exemption. 7-hydroxymitragynine itself is not scheduled as of this writing, but the DEA filed a notice of intent on 1 July 2026 proposing Schedule I control above 0.050% by dry weight or 1.00 mg per article, and indicated an order could issue on or after 5 August 2026. Check the current position before you buy anything in this category.

Who Press’d Botanicals are?

Press’d Botanicals is a US brand in the pressed-tablet segment of the kratom market. Rather than selling loose leaf powder or capsules, the company presses standardized tablets, which is the format that has come to dominate the higher-alkaloid end of the category over the past two years.

The brand sells through smoke shops, convenience retail and online. As with most brands in this space, the company is young, the product line changes frequently, and the labeling conventions are not standardized against anything external. That last point matters more than it sounds and it comes up again below.

What the tablets are, in plain terms?

A pressed kratom-alkaloid tablet is a compressed dose form containing an extract rather than raw leaf. The extract is standardized to a stated alkaloid content, usually expressed in milligrams per tablet. Products in this segment are commonly labeled around 300 mg, though what that figure refers to differs by brand: sometimes total extract weight, sometimes a specific alkaloid, sometimes something the label does not define.

This is the single most important thing to understand about the category. Two tablets both labeled 300 mg can contain materially different amounts of the alkaloids that actually do anything, because there is no agreed convention for what the number describes. Independent testing has repeatedly found gaps between labeled and actual content across brands.

Red OH, Extra Strength and the sub-brands

Press’d has run several product lines, including versions marketed as Red OH and as extra-strength tablets. Search interest exists for each individually, which suggests people encounter them separately in retail rather than as a coherent range.

The practical guidance is the same across all of them. The name on the front of the pack tells you nothing verifiable. The certificate of analysis does. If a product line does not have a current, batch-matched COA from an accredited third-party lab, you are relying on the manufacturer’s word about a category the FDA has publicly described as an emerging public health threat.

What is URIQ Complex?

URIQ Complex appears in Press’d marketing as a proprietary blend name. Proprietary blends are worth treating carefully. Under US labeling conventions a proprietary blend can list its components without disclosing the quantity of each, which means the label can be accurate and still tell you very little.

If you want to know what is actually in a product carrying a blend name, the COA is again the only route. Ask for one that matches the batch code printed on the pack, not a generic one from the brand’s website.

How to verify any product in this category?

• Find the batch or lot code on the physical pack. A COA that does not reference your batch is not evidence about your product.
• Check the lab is accredited and independent of the brand. ISO 17025 accreditation is the meaningful marker.
• Read the alkaloid breakdown, not the summary. You want the individual figures for mitragynine and 7-hydroxymitragynine, expressed per unit.
• Check the test date. Extracts change hands and reformulate frequently, and a two-year-old COA describes a product that may no longer exist.
• Confirm the report covers contaminant screening: heavy metals, microbials and residual solvents. Alkaloid content alone is half a picture.

What the federal changes mean in practice?

The August 2026 order is narrow and specific. It controls mitragynine pseudoindoxyl, MGM-15 and MGM-16. It does not control kratom leaf, mitragynine, or 7-OH. If a product contains one of the three scheduled compounds, it is a Schedule I substance regardless of how it is marketed or what the packaging says.

The proposed 7-OH threshold rule is a separate action that has not taken effect. If and when it does, products above 0.050% by dry weight or 1.00 mg per article would fall under Schedule I control. Most concentrated tablets on the market today sit well above that threshold.

State law runs independently of all of this. Several states ban kratom outright, and others regulate it through age restrictions, labeling requirements or registration schemes. Federal status is a floor, not a complete answer.

Frequently asked questions

Q. Is Press’d kratom legal?

Kratom leaf and mitragynine are not federally controlled. Whether a specific Press’d product is legal depends on what it contains and on your state. Products containing mitragynine pseudoindoxyl, MGM-15 or MGM-16 are Schedule I as of 26 August 2026.

Q. Is Press’d a legitimate brand?

It is a real company selling through established retail channels. Legitimacy in this category is better assessed per batch than per brand, using third-party lab results.

Q. What is the difference between “pressd,” “press’d” and “pressed” kratom?

They are all the same brand. The apostrophe is part of the trademark and is frequently dropped in search and in retail listings.

Q. How is this different from regular kratom powder?

Powder is milled leaf. These tablets contain a concentrated extract standardized to a stated alkaloid figure, so the alkaloid content per gram is far higher.

Q. Where can I check current federal status?

The Federal Register and the DEA’s Diversion Control Division publish scheduling actions directly. This page was last reviewed in September 2026.

This page is general information about a product category and its regulatory status. It is not medical advice, legal advice, or a recommendation to use any product. Kratom and its concentrated derivatives are not approved by the FDA for any therapeutic use.